Zanamivir | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Zanamivir
HEALTH CANADA PATENTS

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

With Fermion, start the journey of your innovative API.

Contact Supplier

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Zanamivir

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 1 NDC API, 2 Listed Suppliers

2 API Suppliers
1 NDC API
2 Listed Suppliers

FINISHED DOSAGE FORMULATIONS

6 FDF Dossiers, 1 FDA Orange Book, 3 Europe, 1 Canada, 1 South Africa

6 FDF Dossiers
1 FDA Orange Book
3 Europe
1 Canada
1 South Africa

RELATED EXCIPIENT COMPANIES

2 BASF, 3 Kerry, 1 Roquette

2 BASF
3 Kerry
1 Roquette

EXCIPIENTS BY APPLICATIONS

3 Co-Processed Excipients, 2 Granulation, 2 Direct Compression, 1 Coating Systems & Additives, 1 Controlled & Modified Release, 1 Fillers, Diluents & Binders

3 Co-Processed Excipients
2 Granulation
2 Direct Compression
1 Coating Systems & Additives
1 Controlled & Modified Release
1 Fillers, Diluents & Binders

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 8 NEWS #PharmaBuzz

2 DATA COMPILATION #PharmaFlow
8 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 2 Finished Drug Prices

1 US Medicaid Prescriptions
2 Finished Drug Prices

MARKET PLACE

1 APIs, 1 EXCIPIENTS

1 APIs
1 EXCIPIENTS

PATENTS & EXCLUSIVITIES

3 Health Canada Patents

3 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 USP, 3 Others

3 USP
3 Others

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

3 All

01 3GlaxoSmithKline Inc.

filter Patent Reset all filters

3 All

01 12081356

02 12177990

03 12291994

filter Product Reset all filters

3 All

01 3Zanamivir

filter Dosage Reset all filters

3 All

01 3Dry Powder Inhaler

filter Exp Date Reset all filters

3 All

01 22011-04-24

02 12014-12-15

Product Main Page

01

GlaxoSmithKline Inc.

Zanamivir

Antibody Engineering

Not Confirmed

GlaxoSmithKline Inc.

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-04-24

Date Granted : 2003-10-14

Brand Name : RELENZA

Patent Number : 2291994

Filing Date : 1991-04-24

Strength per Unit : 5mg/blister

Dosage Form : Dry Powder Inhaler

Human Or VET : Human

Route of Administration : Oral Inhalation

Patent Expiration Date : 2011-04-24

Date Granted : 2003-10-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

GlaxoSmithKline Inc.

Zanamivir

Antibody Engineering

Not Confirmed

GlaxoSmithKline Inc.

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-04-24

Date Granted : 2000-02-22

Brand Name : RELENZA

Patent Number : 2081356

Filing Date : 1991-04-24

Strength per Unit : 5mg/blister

Dosage Form : Dry Powder Inhaler

Human Or VET : Human

Route of Administration : Oral Inhalation

Patent Expiration Date : 2011-04-24

Date Granted : 2000-02-22

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

GlaxoSmithKline Inc.

Zanamivir

Antibody Engineering

Not Confirmed

GlaxoSmithKline Inc.

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2014-12-15

Date Granted : 2000-04-25

Brand Name : RELENZA

Patent Number : 2177990

Filing Date : 1994-12-15

Strength per Unit : 5mg/blister

Dosage Form : Dry Powder Inhaler

Human Or VET : Human

Route of Administration : Oral Inhalation

Patent Expiration Date : 2014-12-15

Date Granted : 2000-04-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?